Shanghai SiPenoin Biotechnology

Shanghai SiPenoin Biotechnology (also known as Spot Biosystems) is a clinical-stage biotechnology company specializing in the development of mRNA-based therapeutics delivered via extracellular vesicles (EVs). The company's lead program, SPOT-mRNA03, is a first-in-class gene therapy for Duchenne Muscular Dystrophy (DMD) that delivers full-length dystrophin mRNA directly to muscle cells. By utilizing proprietary molecular targeting peptides on the EV membrane, the platform aims to achieve high-precision delivery with low immunogenicity. Founded by physician-scientists from Stanford and Ohio State University, the company is advancing its pipeline to address rare diseases, oncology, and protein replacement therapies.